Drugs / WJ-MSC- Exosomes
WJ-MSC- Exosomes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06812637 | Apr → Jun 2024 | ulcer of lower limbs | Kafrelsheikh University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WJ-MSC- Exosomes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06812637 ↗ |
| Known as | Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes | “Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial” NCT06812637 ↗ |
| Known as | WJ-MSC derived exosomes | “Study effeciency and safety of WJ-MSC derived exosomes in DFU healing” NCT06812637 ↗ |
| Modality | Other / unclassified | “Exosomes are small extracellular vesicles that facilitate intercellular communication by transporting proteins, lipids, and nucleic acids.” NCT06812637 ↗ |
| Route | Topical | “topical application of WJ-MSC-derived exosomes” NCT06812637 ↗ |